MAH0 Stock Overview
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.55 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.85 |
| Beta | 0.78 |
| 1 Month Change | -4.14% |
| 3 Month Change | -20.81% |
| 1 Year Change | 131.82% |
| 3 Year Change | -8.93% |
| 5 Year Change | -38.72% |
| Change since IPO | -48.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAH0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.5% |
| 1Y | 131.8% | -22.8% | 1.3% |
Price Volatility
| MAH0 volatility | |
|---|---|
| MAH0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MAH0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MAH0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
| MAH0 fundamental statistics | |
|---|---|
| Market cap | €363.07m |
| Earnings (TTM) | -€27.49m |
| Revenue (TTM) | €9.33m |
39.3x
P/S Ratio-13.4x
P/E RatioIs MAH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAH0 income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$2.57m |
| Gross Profit | US$7.43m |
| Other Expenses | US$36.89m |
| Earnings | -US$29.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 74.26% |
| Net Profit Margin | -294.66% |
| Debt/Equity Ratio | 8.7% |
How did MAH0 perform over the long term?
See historical performance and comparison